Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04819100 · ClinicalTrials.gov registry record · Phase 3
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 152
- Enrollment target
- 20
- Study locations
NCT04819100 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 152 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT04819100, a Phase 3 study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 152 participants
- Enrollment target
- 20
- Study locations
Study Summary
The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Selpercatinib
Study Locations (20)
California
- UCLA Hematology/Oncology - Santa Monica - Los Angeles
- Stockton Hematology Oncology Group - Stockton
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center - Torrance
Florida
- GenesisCare - Aventura
- GenesisCare - Boca Raton - Boca Raton
- USO-Cancer Care Center of Brevard, Inc. - Palm Bay
Queensland
- Sunshine Coast University Hospital - Birtinya
- Rockhampton Hospital - Rockhampton
- The Townsville Hospital - Townsville
New York
- USO-New York Oncology Hematology, P.C - Latham
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Sarah Cannon Research Institute SCRI - Nashville
- Tennessee Oncology Nashville - Nashville
Texas
- USO-Texas Oncology-Central/South Texas - Austin
- US Oncology - The Woodlands
Victoria
- Ballarat Health Services - Ballarat Central
- Bendigo Health Care Group - Bendigo
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2021-12-20 |
| Est. Completion | 2028-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04819100
The ClinicalTrials.gov registry entry for NCT04819100 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (53% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04819100 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Queensland.
Frequently Asked Questions
What is clinical trial NCT04819100 about?
NCT04819100 is a clinical study titled "A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)". The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop ...
What is the current status of trial NCT04819100?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2021-12-20. Estimated completion is 2028-05.
What conditions does trial NCT04819100 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT04819100?
The interventions under investigation include: Placebo (DRUG), Selpercatinib (DRUG).
Who is sponsoring clinical trial NCT04819100?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04819100 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RECRUITING · Phase 3
-
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.